Drug-related infectious diseases in Europe: update from the EMCDDA expert network
This report provides an update on infectious diseases related to injecting drug use in Europe. It covers both the EMCDDA Drug-related infectious diseases indicator, which collects data on the situation, and the responses in the area. The report is based on the indicator’s annual expert meeting,...
New psychoactive substances in Europe: legislation and prosecution — current challenges and solutions
The European new psychoactive substances (NPS) market has increased at a speed that established drug control laws struggle to match. Various countries have therefore introduced new legal responses to this phenomenon, based either on existing laws that focused on consumer or health protection or...
Drugnet Europe 96
In this issue: EMCDDA scientific award 2016 | Lisbon Addictions 2017 | New report on drug‑related hospital emergencies | Grounds for hope in treating hepatitis C | EC proposes amendment to EMCDDA founding regulation | New products and services | EMCDDA Director pays official visit to Europol
How can contingency management support treatment for substance use disorders? A systematic review
Contingency management is a general behavioural intervention technique used in the treatment of drug dependence. This EMCDDA Paper contains a systematic review of studies on the effectiveness of contingency management when used alongside the pharmacological treatment of dependence. The 38 studies...
Country Drug Report
Moldova country overview
This summary was drafted by the National Drug Observatory of the Republic of Moldova in the framework of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) technical cooperation project ‘Towards a gradual improvement of European Neighbourhood Policy partner countries’ capacity to...
ESPAD Report 2015 — Results from the European School Survey Project on Alcohol and Other Drugs
This report presents the most recent and comprehensive data on substance use among 15- to 16-year-old school students in Europe. Based on the responses from over 90 000 girls and boys, the report documents the levels of use of tobacco, alcohol, cannabis and other substances, as well as the...
EU Drug Markets Report: promotional brochure
This brochure offers an overview of the latest EU Drug Markets Report, from the EMCDDA and Europol. Published every three years, the report provides a state-of-the-art analysis of the illicit drug market, covering trends along the supply chain from production and trafficking to marketing,...
Hospital emergency presentations and acute drug toxicity in Europe — update from the Euro-DEN Plus research group and the EMCDDA
This rapid communication provides an update on drug related hospital emergency presentations in Europe with a specific focus on the latest results for acute drug toxicity presentations to the European Drug Emergencies Network (Euro-DEN). This report is primarily based on presentations and...
Hepatitis C among drug users in Europe: epidemiology, treatment and prevention
Hepatitis C among drug users in Europe: epidemiology, treatment and prevention provides a timely contribution to raising awareness of the hepatitis C epidemic in Europe and the opportunities now opening up to tackle this problem decisively. A state-of-the-art review of the epidemiology of hepatitis...
Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP)
This publication presents the data and findings of the risk assessment on α-PVP (1-phenyl- 2-(1-pyrrolidinyl)-1-pentanone), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2015. α-PVP is the eleventh new psychoactive substance to be risk assessed under the terms of...
EMCDDA–Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA
This report presents the key activities performed by the EMCDDA and Europol in 2015 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2015...
EMCDDA–Europol Joint Report on MDMB-CHMICA
In February 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA, through a joint assessment. The two organisations concluded that sufficient...
Health responses to new psychoactive substances
While prevalence levels of NPS use remain low in the general European population, there are important concerns with more problematic forms of use and harms. This short report provides an overview of the current situation in terms of NPS use and harms across Europe and reviews the available health-...
Perspectives on Drugs (PODs)
Health responses to new psychoactive substances (Perspectives on Drugs)
The emergence of new psychoactive substances (NPS) over the last decade has posed a major challenge to drug policy. While the limited available data indicates that prevalence levels of NPS use are relatively low in the general European population, there are concerns around more problematic forms of...
Country Drug Report
Ukraine country overview
This summary was prepared based on Pinchuk, I.J, Shum, S.S., Rumyantseva, S.S. et al. (2014), ‘2014 National report (2013 data) to the European Monitoring Centre for Drugs and Drug Addiction. It was last updated in 2016 and is available in online (HTML) format only.
Country Drug Report
Israel country overview
This summary was prepared in the framework of the EMCDDA technical cooperation project ‘Towards a gradual improvement of ENP partner countries’ capacity to monitor and to meet drug-related challenges’ (ENPI), funded by the European Commission. The content of this summary does not necessarily...
General report of activities
General Report of Activities 2015 — Key achievements and governance: a year in review
The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme. The report is a useful information source for all those seeking...